Previous Close | 2.5600 |
Open | 2.5900 |
Bid | 2.7200 x 200 |
Ask | 2.7700 x 200 |
Day's Range | 2.5500 - 2.8250 |
52 Week Range | 1.3300 - 4.2980 |
Volume | |
Avg. Volume | 444,503 |
Market Cap | 105.015M |
Beta (5Y Monthly) | 2.85 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and dementia with Lewy bodies Results from exploratory SHAPE Phase 2 trial show encouraging safety and pro-cognitive measures with fosgonimeton treatment and underscore confidence in Phase 2/3 LIFT-AD trial with data anticipated in the second half of 2024 BOTHELL, Wash., March 08
Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease; topline data expected in second half of 2024 On track to initiate first-in-human studies of ATH-1105 for the treatment of amyotrophic lateral sclerosis in first half of 2024 Strong balance sheet to support innovative pipeline through key inflection points BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-st
Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALSBOTHELL, Wash., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of